Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders.

Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders..

World J Biol Psychiatry. 2002 Oct;3(4):171-99. Review.

PMID:
12516310
2.

Spotlight on paroxetine in psychiatric disorders in adults.

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL.

CNS Drugs. 2002;16(6):425-34. Review.

PMID:
12027788
3.

SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.

Asnis GM, Kohn SR, Henderson M, Brown NL.

Drugs. 2004;64(4):383-404. Review.

PMID:
14969574
4.

The medical treatment of obsessive-compulsive disorder and anxiety.

Bandelow B.

CNS Spectr. 2008 Sep;13(9 Suppl 14):37-46. Review.

PMID:
18849910
5.

Recent advances in the psychopharmacological treatment of anxiety disorders.

Lydiard RB, Roy-Byrne PP, Ballenger JC.

Hosp Community Psychiatry. 1988 Nov;39(11):1157-65. Review.

PMID:
2906319
6.

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

Zohar J, Westenberg HG.

Acta Psychiatr Scand Suppl. 2000;403:39-49. Review.

PMID:
11019934
7.

[Neurobiology and pharmacotherapy of social phobia].

Aouizerate B, Martin-Guehl C, Tignol J.

Encephale. 2004 Jul-Aug;30(4):301-13. Review. French.

PMID:
15538306
8.

Antidepressant drugs in anxiety disorders.

Modigh K.

Acta Psychiatr Scand Suppl. 1987;335:57-74. Review.

PMID:
3314359
9.

Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.

Marazziti D, Carlini M, Dell'Osso L.

Curr Top Med Chem. 2012;12(4):238-53. Review.

PMID:
22204483
10.

[Pharmacological treatment of generalized anxiety disorders: rationale and limitations].

Boulenger JP, Capdevielle D.

Encephale. 2007 Jan-Feb;33(1):84-94. Review. French.

PMID:
17457298
11.

[Documented effects of SSRI preparations in anxiety].

Allgulander C.

Lakartidningen. 1998 May 20;95(21):2464-7. Review. Swedish.

PMID:
9640919
12.

Facing the challenge of social anxiety disorder.

Westenberg HG.

Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S93-9. Review.

PMID:
10523064
13.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
14.

[Pharmacotherapy of anxiety disorders].

Inoue T.

Seishin Shinkeigaku Zasshi. 2012;114(9):1085-92. Review. Japanese.

PMID:
23198599
15.

[Current drug treatment. Effects of antidepressive agents in nervous and stress-related disorders].

Rosenberg R.

Ugeskr Laeger. 2001 Apr 2;163(14):1985-91. Review. Danish.

PMID:
11307357
16.

Overview of diagnosis and drug treatments of anxiety disorders.

Nutt DJ.

CNS Spectr. 2005 Jan;10(1):49-56. Review.

PMID:
15618947
17.

Buspirone: future directions.

Apter JT, Allen LA.

J Clin Psychopharmacol. 1999 Feb;19(1):86-93. Review.

PMID:
9934947
18.

Venlafaxine in the treatment of anxiety disorders.

Katzman M.

Expert Rev Neurother. 2004 May;4(3):371-81. Review.

PMID:
15853535
19.

Spotlight on fluvoxamine in anxiety disorders in children and adolescents.

Cheer SM, Figgitt DP.

CNS Drugs. 2002;16(2):139-44. Review.

PMID:
11825104
20.

Treating comorbid depression and anxiety.

Kuzel RJ.

J Fam Pract. 1996 Dec;43(6 Suppl):S45-53. Review.

PMID:
8969712

Supplemental Content

Support Center